Temperature Treatment of Highly Porous Zirconium-Containing Metal-Organic Frameworks Extends Drug Delivery Release

Michelle H. Teplensky, Marcus Fantham, Peng Li, Timothy C. Wang, Joshua P. Mehta, Laurence J. Young, Peyman Z. Moghadam, Joseph T Hupp, Omar K. Farha, Clemens F. Kaminski, David Fairen-Jimenez

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Utilizing metal-organic frameworks (MOFs) as a biological carrier can lower the amount of the active pharmaceutical ingredient (API) required in cancer treatments to provide a more efficacious therapy. In this work, we have developed a temperature treatment process for delaying the release of a model drug compound from the pores of NU-1000 and NU-901, while taking care to utilize these MOFs' large pore volume and size to achieve exceptional model drug loading percentages over 35 wt %. Video-rate super-resolution microscopy reveals movement of MOF particles when located outside of the cell boundary, and their subsequent immobilization when taken up by the cell. Through the use of optical sectioning structured illumination microscopy (SIM), we have captured high-resolution 3D images showing MOF uptake by HeLa cells over a 24 h period. We found that addition of a model drug compound into the MOF and the subsequent temperature treatment process does not affect the rate of MOF uptake by the cell. Endocytosis analysis revealed that MOFs are internalized by active transport and that inhibiting the caveolae-mediated pathway significantly reduced cellular uptake of MOFs. Encapsulation of an anticancer therapeutic, alpha-cyano-4-hydroxycinnamic acid (α-CHC), and subsequent temperature treatment produced loadings of up to 81 wt % and demonstrated efficacy at killing cells beyond the burst release effect.

Original languageEnglish
Pages (from-to)7522-7532
Number of pages11
JournalJournal of the American Chemical Society
Volume139
Issue number22
DOIs
Publication statusPublished - Jun 7 2017

Fingerprint

Drug delivery
Zirconium
Metals
Temperature
Pharmaceutical Preparations
Microscopy
Microscopic examination
Caveolae
Oncology
Drug Liberation
Active Biological Transport
Endocytosis
Lighting
HeLa Cells
Encapsulation
Immobilization
Drug products
Acids
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Catalysis
  • Chemistry(all)
  • Biochemistry
  • Colloid and Surface Chemistry

Cite this

Teplensky, M. H., Fantham, M., Li, P., Wang, T. C., Mehta, J. P., Young, L. J., ... Fairen-Jimenez, D. (2017). Temperature Treatment of Highly Porous Zirconium-Containing Metal-Organic Frameworks Extends Drug Delivery Release. Journal of the American Chemical Society, 139(22), 7522-7532. https://doi.org/10.1021/jacs.7b01451

Temperature Treatment of Highly Porous Zirconium-Containing Metal-Organic Frameworks Extends Drug Delivery Release. / Teplensky, Michelle H.; Fantham, Marcus; Li, Peng; Wang, Timothy C.; Mehta, Joshua P.; Young, Laurence J.; Moghadam, Peyman Z.; Hupp, Joseph T; Farha, Omar K.; Kaminski, Clemens F.; Fairen-Jimenez, David.

In: Journal of the American Chemical Society, Vol. 139, No. 22, 07.06.2017, p. 7522-7532.

Research output: Contribution to journalArticle

Teplensky, MH, Fantham, M, Li, P, Wang, TC, Mehta, JP, Young, LJ, Moghadam, PZ, Hupp, JT, Farha, OK, Kaminski, CF & Fairen-Jimenez, D 2017, 'Temperature Treatment of Highly Porous Zirconium-Containing Metal-Organic Frameworks Extends Drug Delivery Release', Journal of the American Chemical Society, vol. 139, no. 22, pp. 7522-7532. https://doi.org/10.1021/jacs.7b01451
Teplensky, Michelle H. ; Fantham, Marcus ; Li, Peng ; Wang, Timothy C. ; Mehta, Joshua P. ; Young, Laurence J. ; Moghadam, Peyman Z. ; Hupp, Joseph T ; Farha, Omar K. ; Kaminski, Clemens F. ; Fairen-Jimenez, David. / Temperature Treatment of Highly Porous Zirconium-Containing Metal-Organic Frameworks Extends Drug Delivery Release. In: Journal of the American Chemical Society. 2017 ; Vol. 139, No. 22. pp. 7522-7532.
@article{3bf30422d23946a892ddbe7e5a34c47e,
title = "Temperature Treatment of Highly Porous Zirconium-Containing Metal-Organic Frameworks Extends Drug Delivery Release",
abstract = "Utilizing metal-organic frameworks (MOFs) as a biological carrier can lower the amount of the active pharmaceutical ingredient (API) required in cancer treatments to provide a more efficacious therapy. In this work, we have developed a temperature treatment process for delaying the release of a model drug compound from the pores of NU-1000 and NU-901, while taking care to utilize these MOFs' large pore volume and size to achieve exceptional model drug loading percentages over 35 wt {\%}. Video-rate super-resolution microscopy reveals movement of MOF particles when located outside of the cell boundary, and their subsequent immobilization when taken up by the cell. Through the use of optical sectioning structured illumination microscopy (SIM), we have captured high-resolution 3D images showing MOF uptake by HeLa cells over a 24 h period. We found that addition of a model drug compound into the MOF and the subsequent temperature treatment process does not affect the rate of MOF uptake by the cell. Endocytosis analysis revealed that MOFs are internalized by active transport and that inhibiting the caveolae-mediated pathway significantly reduced cellular uptake of MOFs. Encapsulation of an anticancer therapeutic, alpha-cyano-4-hydroxycinnamic acid (α-CHC), and subsequent temperature treatment produced loadings of up to 81 wt {\%} and demonstrated efficacy at killing cells beyond the burst release effect.",
author = "Teplensky, {Michelle H.} and Marcus Fantham and Peng Li and Wang, {Timothy C.} and Mehta, {Joshua P.} and Young, {Laurence J.} and Moghadam, {Peyman Z.} and Hupp, {Joseph T} and Farha, {Omar K.} and Kaminski, {Clemens F.} and David Fairen-Jimenez",
year = "2017",
month = "6",
day = "7",
doi = "10.1021/jacs.7b01451",
language = "English",
volume = "139",
pages = "7522--7532",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",
number = "22",

}

TY - JOUR

T1 - Temperature Treatment of Highly Porous Zirconium-Containing Metal-Organic Frameworks Extends Drug Delivery Release

AU - Teplensky, Michelle H.

AU - Fantham, Marcus

AU - Li, Peng

AU - Wang, Timothy C.

AU - Mehta, Joshua P.

AU - Young, Laurence J.

AU - Moghadam, Peyman Z.

AU - Hupp, Joseph T

AU - Farha, Omar K.

AU - Kaminski, Clemens F.

AU - Fairen-Jimenez, David

PY - 2017/6/7

Y1 - 2017/6/7

N2 - Utilizing metal-organic frameworks (MOFs) as a biological carrier can lower the amount of the active pharmaceutical ingredient (API) required in cancer treatments to provide a more efficacious therapy. In this work, we have developed a temperature treatment process for delaying the release of a model drug compound from the pores of NU-1000 and NU-901, while taking care to utilize these MOFs' large pore volume and size to achieve exceptional model drug loading percentages over 35 wt %. Video-rate super-resolution microscopy reveals movement of MOF particles when located outside of the cell boundary, and their subsequent immobilization when taken up by the cell. Through the use of optical sectioning structured illumination microscopy (SIM), we have captured high-resolution 3D images showing MOF uptake by HeLa cells over a 24 h period. We found that addition of a model drug compound into the MOF and the subsequent temperature treatment process does not affect the rate of MOF uptake by the cell. Endocytosis analysis revealed that MOFs are internalized by active transport and that inhibiting the caveolae-mediated pathway significantly reduced cellular uptake of MOFs. Encapsulation of an anticancer therapeutic, alpha-cyano-4-hydroxycinnamic acid (α-CHC), and subsequent temperature treatment produced loadings of up to 81 wt % and demonstrated efficacy at killing cells beyond the burst release effect.

AB - Utilizing metal-organic frameworks (MOFs) as a biological carrier can lower the amount of the active pharmaceutical ingredient (API) required in cancer treatments to provide a more efficacious therapy. In this work, we have developed a temperature treatment process for delaying the release of a model drug compound from the pores of NU-1000 and NU-901, while taking care to utilize these MOFs' large pore volume and size to achieve exceptional model drug loading percentages over 35 wt %. Video-rate super-resolution microscopy reveals movement of MOF particles when located outside of the cell boundary, and their subsequent immobilization when taken up by the cell. Through the use of optical sectioning structured illumination microscopy (SIM), we have captured high-resolution 3D images showing MOF uptake by HeLa cells over a 24 h period. We found that addition of a model drug compound into the MOF and the subsequent temperature treatment process does not affect the rate of MOF uptake by the cell. Endocytosis analysis revealed that MOFs are internalized by active transport and that inhibiting the caveolae-mediated pathway significantly reduced cellular uptake of MOFs. Encapsulation of an anticancer therapeutic, alpha-cyano-4-hydroxycinnamic acid (α-CHC), and subsequent temperature treatment produced loadings of up to 81 wt % and demonstrated efficacy at killing cells beyond the burst release effect.

UR - http://www.scopus.com/inward/record.url?scp=85020462845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020462845&partnerID=8YFLogxK

U2 - 10.1021/jacs.7b01451

DO - 10.1021/jacs.7b01451

M3 - Article

C2 - 28508624

AN - SCOPUS:85020462845

VL - 139

SP - 7522

EP - 7532

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

IS - 22

ER -